피부경화증 진단 및 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)
Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
상품코드:1402924
리서치사:Transparency Market Research
발행일:2023년 11월
페이지 정보:영문 176 Pages
라이선스 & 가격 (부가세 별도)
한글목차
피부경화증 진단 및 치료 시장 - 보고서 범위
TMR의 세계 피부경화증 진단 및 치료 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻을 수 있는 기회를 연구하고 있습니다. 이 보고서는 전 세계 피부경화증 진단 및 치료제의 수익을 제공합니다. 2023년을 기준 연도로, 2031년을 예측 연도로 간주하여 2017-2031년 기간 동안 치료제 시장을 분석합니다. 이 보고서는 또한 2023년부터 2031년까지 세계 피부경화증 진단 및 치료제 시장의 복합 연간 성장률(CAGR %)을 제공합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 대부분의 조사 활동은 애널리스트가 주요 오피니언 리더, 업계 리더 및 오피니언 메이커를 인터뷰하는 방식으로 이루어졌습니다. 2차 조사에는 피부경화증 진단 및 치료 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.
시장 스냅샷
2023년 시장 가치
22억 달러
2031년 시장 가치
46억 달러
CAGR
8.7%
이 보고서는 세계 피부경화증 진단 및 치료 시장의 경쟁 구도에 대해 자세히 분석합니다. 세계 피부경화증 진단 및 치료 시장에서 활동하는 주요 기업이 확인되었으며, 각 기업은 다양한 속성 측면에서 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에 소개된 세계 피부경화증 진단 및 치료제 시장의 기업 속성입니다.
목차
제1장 주요 요약
제2장 시장 개요
시장 세분화
시장 동향
시장 역학
Porter's Five Forces 분석
규제 분석
밸류체인 분석
제품 사양 분석
제조 공정 개요
비용 구조 분석
제3장 COVID-19 감염증의 영향 분석
제4장 가격 동향 분석
제5장 세계 시장 분석과 예측 : 약제 클래스별, 2023-2031년
서론과 정의
세계 시장 금액 예측 : 약제 클래스별, 2023-2031년
코르티코스테로이드
면역억제제
엔도텔린 수용체 작용제
칼슘 채널 차단제
PD5 억제제
킬레이트제
프로스타사이클린 유사체
H2 차단제
양성자 펌프 억제제
ACE 억제제
세계 시장 매력 : 약제 클래스별
제6장 세계 시장 분석과 예측 : 적응증별, 2023-2031년
서론과 정의
세계 시장 금액 예측 : 지표별, 2023-2031년
전신성
국소
세계 시장 매력 : 적응증별
제7장 세계 시장 분석과 예측 : 진단 검사 유형별, 2023-2031년
서론과 정의
세계 시장 금액 예측 : 진단 검사 유형별, 2023-2031년
피부 생검
이미징 기술
혈액 검사
심전도와 심에코도
폐기능 검사
세계 시장 매력도 : 진단 검사 종류별
제8장 세계 시장 분석과 예측 : 지역별, 2023-2031년
주요 조사 결과
세계 시장 금액 예측 : 지역별, 2023-2031년
북미
유럽
아시아태평양
중동 및 아프리카
라틴아메리카
세계 시장 매력 : 지역별
제9장 북미 시장 분석과 예측, 2023-2031년
제10장 유럽 시장 분석과 예측, 2023-2031년
제11장 아시아태평양 시장 분석과 예측, 2023-2031년
제12장 라틴아메리카 시장 분석과 예측, 2023-2031년
제13장 중동 및 아프리카 시장 분석과 예측, 2023-2031년
제14장 경쟁 상황
세계 기업의 시장 점유율 분석, 2022년
기업 개요(상세 - 개요, 재무, 최근의 전개, 전략)
Johnson &Johnson Services, Inc.
Boehringer Ingelheim
Bayer AG
Cytori Therapeutics, Inc.
Corbus Pharmaceuticals Holdings Inc.
Cumberland Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Sanofi SA
Pfizer Inc.
F. Hoffmann-La Roche AG
Merck &Co., Inc.
제15장 1차 조사 : 중요한 인사이트
제16장 부록
ksm
영문 목차
영문목차
Scleroderma Diagnostics and Therapeutics Market - Scope of Report
TMR's report on the global scleroderma diagnostics and therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global scleroderma diagnostics and therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global scleroderma diagnostics and therapeutics market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the scleroderma diagnostics and therapeutics market.
Market Snapshot
Market Value in 2023
US$ 2.2 Bn
Market Value in 2031
US$ 4.6 Bn
CAGR
8.7%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global scleroderma diagnostics and therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global scleroderma diagnostics and therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global scleroderma diagnostics and therapeutics market.
The report delves into the competitive landscape of the global scleroderma diagnostics and therapeutics market. Key players operating in the global scleroderma diagnostics and therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global scleroderma diagnostics and therapeutics market profiled in this report.
Key Questions Answered in Global scleroderma diagnostics and therapeutics Market Report:
What is the sales/revenue generated by scleroderma diagnostics and therapeutics across all regions during the forecast period?
What are the opportunities in the global scleroderma diagnostics and therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Scleroderma Diagnostics and Therapeutics Market - Research Objectives and Research Approach
The comprehensive report on the global scleroderma diagnostics and therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global scleroderma diagnostics and therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global scleroderma diagnostics and therapeutics market.
Table of Contents
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Key Facts and Figures
1.4. Trends Impacting Market
1.5. TMR's Growth Opportunity Wheel
2. Market Overview
2.1. Market Segmentation
2.2. Market Trends
2.3. Market Dynamics
2.3.1. Drivers
2.3.2. Restraints
2.3.3. Opportunities
2.4. Porter's Five Forces Analysis
2.5. Regulatory Analysis
2.6. Value Chain Analysis
2.6.1. List of Raw Material Suppliers
2.6.2. List of Key Manufacturers
2.6.3. List of Suppliers/ Distributors
2.6.4. List of Potential Customers
2.7. Product Specification Analysis
2.8. Overview of Manufacturing Process
2.9. Cost Structure Analysis
3. COVID-19 Impact Analysis
4. Price Trend Analysis
5. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Drug Class, 2023-2031
5.1. Introduction and Definitions
5.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
5.2.1. Corticosteroids
5.2.2. Immunosuppressive Agents
5.2.3. Endothelin Receptor Agonists
5.2.4. Calcium Channel Blockers
5.2.5. PD5-Inhibitors
5.2.6. Chelating Agents
5.2.7. Prostacyclin Analogues
5.2.8. H2 Blockers
5.2.9. Proton Pump Inhibitors
5.2.10. ACE Inhibitors
5.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Drug Class
6. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Indication, 2023-2031
6.1. Introduction and Definitions
6.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
6.2.1. Systemic
6.2.2. Localized
6.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Indication
7. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Diagnostic Test Type, 2023-2031
7.1. Introduction and Definitions
7.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
7.2.1. Skin Biopsy
7.2.2. Imaging Techniques
7.2.3. Blood Test
7.2.4. Electrocardiogram and Echocardiogram
7.2.5. Pulmonary Function Tests
7.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Diagnostic Test Type
8. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Region, 2023-2031
8.1. Key Findings
8.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Region, 2023-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Middle East & Africa
8.2.5. Latin America
8.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Region
9. North America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031
9.1. Key Findings
9.2. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
9.3. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
9.4. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
9.5. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country, 2023-2031
9.5.1. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
9.5.2. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
9.5.3. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
9.5.4. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
9.5.5. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
9.5.6. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
9.6. North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
10. Europe Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031
10.1. Key Findings
10.2. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
10.3. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
10.4. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
10.5. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
10.5.1. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
10.5.2. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
10.5.3. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
10.5.4. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
10.5.5. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
10.5.6. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
10.5.7. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
10.5.8. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
10.5.9. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
10.5.10. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
10.5.11. Italy. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
10.5.12. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
10.5.13. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
10.5.14. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
10.5.15. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
10.5.16. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
10.5.17. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
10.5.18. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
10.6. Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
11. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031
11.1. Key Findings
11.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class
11.3. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
11.4. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
11.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
11.5.1. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
11.5.2. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
11.5.3. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
11.5.4. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
11.5.5. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
11.5.6. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
11.5.7. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
11.5.8. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
11.5.9. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
11.5.10. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
11.5.11. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
11.5.12. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
11.5.13. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
11.5.14. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
11.5.15. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
11.6. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
12. Latin America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031
12.1. Key Findings
12.2. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
12.3. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
12.4. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
12.5. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
12.5.1. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
12.5.2. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
12.5.3. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
12.5.4. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
12.5.5. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
12.5.6. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
12.5.7. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
12.5.8. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
12.5.9. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
12.6. Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
13. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031
13.1. Key Findings
13.2. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
13.3. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
13.4. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
13.5. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
13.5.1. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
13.5.2. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
13.5.3. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
13.5.4. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
13.5.5. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
13.5.6. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
13.5.7. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
13.5.8. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
13.5.9. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
13.6. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
14. Competition Landscape
14.1. Global Scleroderma Diagnostics and Therapeutics Company Market Share Analysis, 2022
14.2. Company Profiles (Details - Overview, Financials, Recent Developments, and Strategy)
